Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel oral therapies for central nervous system (CNS) disorders. Its portfolio includes FDA-approved products for major depressive disorder, excessive daytime sleepiness, and acute migraine treatment, alongside late-stage candidates for Alzheimer’s agitation, narcolepsy, fibromyalgia, and other CNS conditions. Axsome leverages proprietary formulation technologies and targets underserved CNS markets with high unmet medical needs, primarily serving patients and healthcare providers in the U.S.
This description was generated via AI from an annual report. Updated about 1 year ago.